Journal of Hepatocellular Carcinoma (May 2024)
CRISPR in Targeted Therapy and Adoptive T Cell Immunotherapy for Hepatocellular Carcinoma
Abstract
Fahreddin Palaz,1,2 Mehmet Ozsoz,3 Ali Zarrinpar,4,5 Ilyas Sahin5,6 1Department of Medicine, Massachusetts General Hospital, Harvard Medical School, Boston, MA, USA; 2Faculty of Medicine, Hacettepe University, Ankara, Turkey; 3Department of Biomedical Engineering, Near East University, Nicosia, Turkey; 4Department of Surgery, College of Medicine, University of Florida, Gainesville, FL, USA; 5University of Florida Health Cancer Center, Gainesville, FL, USA; 6Division of Hematology and Oncology, Department of Medicine, University of Florida, Gainesville, FL, USACorrespondence: Ilyas Sahin, Email [email protected]: Despite recent therapeutic advancements, outcomes for advanced hepatocellular carcinoma (HCC) remain unsatisfactory, highlighting the need for novel treatments. The CRISPR (Clustered Regularly Interspaced Short Palindromic Repeats) gene-editing technology offers innovative treatment approaches, involving genetic manipulation of either cancer cells or adoptive T cells to combat HCC. This review comprehensively assesses the applications of CRISPR systems in HCC treatment, focusing on in vivo targeting of cancer cells and the development of chimeric antigen receptor (CAR) T cells and T cell receptor (TCR)-engineered T cells. We explore potential synergies between CRISPR-based cancer therapeutics and existing treatment options, discussing ongoing clinical trials and the role of CRISPR technology in improving HCC treatment outcomes with advanced safety measures. In summary, this review provides insights into the promising prospects and current challenges of using CRISPR technology in HCC treatment, with the ultimate goal of improving patient outcomes and revolutionizing the landscape of HCC therapeutics.Keywords: CRISPR, hepatocellular carcinoma, HCC, targeted cancer therapy, adoptive T cell immunotherapy, CAR T cell therapy
